169045-04-9 Usage
General Description
2-Amino-5-bromo-4-methoxybenzoic acid is a chemical compound with the molecular formula C8H8BrNO3. It includes chemical elements such as carbon, hydrogen, bromine, nitrogen and oxygen. The compound has a molar mass of about 246.06 g/mol. This chemical features several functional groups, including an amino group (-NH2), a bromo group (-Br), a methoxy group (-OCH3) and a carboxylic acid group (-COOH). Its applications or uses are not widely documented showing it may be primarily used for scientific research in labs. As with all chemicals, appropriate safety measures should be taken when handling 2-Amino-5-bromo-4-methoxybenzoic acid. Other specific properties, such as its melting point, boiling point, and risk and safety statements, may vary and should be researched independently for accurate information.
Check Digit Verification of cas no
The CAS Registry Mumber 169045-04-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,9,0,4 and 5 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 169045-04:
(8*1)+(7*6)+(6*9)+(5*0)+(4*4)+(3*5)+(2*0)+(1*4)=139
139 % 10 = 9
So 169045-04-9 is a valid CAS Registry Number.
169045-04-9Relevant articles and documents
Compound used as kinase inhibitor, and application thereof
-
Paragraph 0052-0053; 0055-0059, (2021/08/21)
The invention relates to a compound used as a kinase inhibitor, and application thereof. The structure of the compound is shown as a formula I in the specification. The compound used as the kinase inhibitor provided by the invention has good inhibitory activity on EGFR and Her2 exon 20 insertion mutation, and has great potential to be developed into drugs for treating related diseases.
QUINAZOLINONE COMPOUNDS
-
Paragraph 0114, (2020/09/12)
New quinazolinone compounds are disclosed, as well as pharmaceutical compositions containing quinazolinones and methods for the treatment of diseases and conditions associated with mitochondrial dysfunction.
QUINAZOLINE COMPOUND FOR EGFR INHIBITION
-
Paragraph 0136-0137, (2019/11/21)
Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.